Abstract

MicroRNA-mediated post-transcriptional regulation plays key roles in stem cell self-renewal and tumorigenesis. However, the in vivo functions of specific microRNAs in controlling mammary stem cell (MaSC) activity and breast cancer formation remain poorly understood. Here we show that miR-31 is highly expressed in MaSC-enriched mammary basal cell population and in mammary tumors, and is regulated by NF-κB signaling. We demonstrate that miR-31 promotes mammary epithelial proliferation and MaSC expansion at the expense of differentiation in vivo. Loss of miR-31 compromises mammary tumor growth, reduces the number of cancer stem cells, as well as decreases tumor-initiating ability and metastasis to the lung, supporting its pro-oncogenic function. MiR-31 modulates multiple signaling pathways, including Prlr/Stat5, TGFβ and Wnt/β-catenin. Particularly, it activates Wnt/β-catenin signaling by directly targeting Wnt antagonists, including Dkk1. Importantly, Dkk1 overexpression partially rescues miR31-induced mammary defects. Together, these findings identify miR-31 as the key regulator of MaSC activity and breast tumorigenesis.

Highlights

  • mammary stem cell (MaSC) are controlled by the dynamic interplay of multiple molecular pathways such as hormone, Notch and Wnt signaling[7, 10, 11]

  • We demonstrate that miR-31 plays an important role in MaSC self-renewal and tumorigenesis by regulating Wnt pathway activation

  • This study is the first to demonstrate the in vivo, physiological role of a specific microRNA in regulating MaSCs and mammary gland development using a loss-of-function mouse model (Supplementary Fig. 9)

Read more

Summary

Introduction

MaSCs are controlled by the dynamic interplay of multiple molecular pathways such as hormone, Notch and Wnt signaling[7, 10, 11]. Wnt/β-Catenin signaling is important for promoting MaSC activity and determining a basal cell fate. By utilizing miR-31 gain− and loss-of-function mouse models, coupled with the MMTVPyVT mammary tumor model, here we demonstrate that miR-31 promotes MaSC activity and breast tumorigenesis by regulating multiple signaling pathways. Chromatin immunoprecipitation (ChIP) assay revealed that p65 binds to its predicted cognate sites in miR-31 promoter, and that RANKL siRNA reduced this binding (Fig. 1h) Together, these data suggest that miR-31 expression is directly activated by NF-κB pathway in the mammary gland. In miR-31 promoter driven-luciferase reporter assays, treatment of estradiol and progesterone enhanced luciferase reporter activity, while mutation of p65-binding sites blocked it (Supplementary Fig. 1f). MiR-31 expression is hormone-responsive, likely through an indirect mechanism that involves the RNAKL/RANK/NF-κB pathway

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call